Polaris Market Research today released findings from its latest industry report, projecting the U.S. Clinical Laboratory Tests market to expand from USD 52.77 Billion in 2024 to USD 95.24 Billion by 2034, registering a CAGR of 6.1% across the forecast period. The report profiles 10 leading companies operating across the market's key segments and regions.

Analyst Commentary on U.S. Clinical Laboratory Tests Market Growth

"Diagnostic testing has moved from a back-office function to a frontline tool for managing chronic disease and personalizing treatment across the U.S. healthcare system" said a senior analyst at Polaris Market Research. "The fastest growth we're seeing isn't in central labs, it's in primary clinics, where point-of-care testing is bringing diagnostics closer to the patient"

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: advancements in diagnostic technologies such as molecular diagnostics and high-throughput sequencing, and a growing elderly population that reached 61.2 million people, or 18% of the U.S. total, in 2024 are the primary forces behind the market's expansion, alongside rising demand for personalized medicine and biomarker-driven diagnostics. In February 2024, Complete Genomics and seqWell expanded their library preparation partnership to enable faster, higher-throughput sequencing workflows.

Major Companies Covered:

• Abbott Laboratories
• ARUP Laboratories
• Charles River Laboratories
• Genoptix, Inc.
• Mayo Clinic Laboratories
• NeoGenomics Laboratories, Inc.
• OPKO Health, Inc.
• Quest Diagnostics

Request for a sample copy of this research report @

https://www.polarismarketresearch.com/industry-analysis/us-clinical-laboratory-tests-market 

Segments Covered: By Type (Clinical Chemistry Testing, Hematology Testing, Immunology & Serology Testing, Molecular Diagnostics, Others), By End Use (Central Laboratories, Primary Clinics).

Recent Developments in the U.S. Clinical Laboratory Tests Market

• April 2025: Quest Diagnostics launched a blood test combining Aβ42/40 and p-tau217 biomarkers to help confirm amyloid pathology in Alzheimer's patients.
• June 2024: PHASE Scientific Americas launched two at-home collection kits for HbA1c and lipid panel testing, expanding self-collected diagnostics.

Market Snapshot: Clinical Chemistry Dominates, Primary Clinics Accelerate

Clinical chemistry testing held the largest share of the U.S. clinical laboratory tests market in 2024, reflecting its central role in managing chronic conditions such as diabetes and cardiovascular disease. By end use, central laboratories remain the largest channel today, but primary clinics are forecast to grow at an 8.7% CAGR through 2034 as decentralized, point-of-care testing expands access to routine and preventive diagnostics at the community level.

Why It Matters for Teams Evaluating Diagnostics Market Entry

For stakeholders researching clinical laboratory tests market forecast, the underlying Polaris Market Research report benchmarks U.S. Clinical Laboratory Tests market share, company positioning, and segment-level forecasts to support sourcing, partnership, and investment decisions through 2034.

Conclusion

The U.S. clinical laboratory tests market is expected to nearly double by 2034, propelled by an aging population, rising chronic disease burden, and rapid adoption of AI-enabled diagnostics. As testing volume shifts toward primary clinics and personalized medicine, companies that can combine scale with fast, decentralized service delivery are best placed to lead the next phase of growth.

More Trending Latest Reports By Polaris Market Research:

Solar Panels Market

Disinfection Robots Market

Home Bedding Market

Rising Need for Early Detection of Diseases Drives Demand for Rapid Medical Diagnostic Kits

EV Connector Market

EV Connector Market

Osteoarthritis Market

Building Automation Market

Spa Market